ArticleInfectious Disease Modelling2022
Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020-2026: A modeling study.
Article in Infectious Disease Modelling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Stochastic control of influenza spread: A Lévy-driven SDE and branching process approach.Infectious Disease Modelling · 2026Article
- Impact of vaccination on Omicron's escape variants: Insights from fine-scale modelling of waning immunity in Hong Kong.Infectious Disease Modelling · 2025Article
- Article
- Mathematical modeling for estimating influenza vaccine efficacy: A case study of the Valencian Community, Spain.Infectious Disease Modelling · 2024Article
- Assessing the dynamics and impact of COVID-19 vaccination on disease spread: A data-driven approach.Infectious Disease Modelling · 2024Article
- Understanding the relationship between stay-at-home measures and vaccine shortages: a conventional, heterogeneous, and fractional dynamic approach.Journal of health, population, and nutrition · 2024Article
- The disutility of compartmental model forecasts during the COVID-19 pandemic.Frontiers in epidemiology · 2024Article
- A note on variable susceptibility, the herd-immunity threshold and modeling of infectious diseases.PloS one · 2023Article
- Downscaling epidemiological time series data for improving forecasting accuracy: An algorithmic approach.PloS one · 2023Article
- Incorporating the mutational landscape of SARS-COV-2 variants and case-dependent vaccination rates into epidemic models.Infectious Disease Modelling · 2022Article
- Adrenomedullin Therapy in Moderate to Severe COVID-19.Biomedicines · 2022Review
- Predicting the Willingness and Purchase of Travel Insurance During the COVID-19 Pandemic.Frontiers in public health · 2022Article
- Water Transmission Increases the Intensity of COVID-19 Outbreaks.Frontiers in public health · 2022Article
- The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBesides maintaining health precautions, vaccination has been the only prevention from SARS-CoV-2, though no clinically proved 100% effective vaccine has been developed till date. At this stage, to withhold the debris of this pandemic-experts need to know the impact of the vaccine efficacy rates, the threshold level of vaccine effectiveness and how long this pandemic may extent with vaccines that have different efficacy rates. In this article, a mathematical model study has been done on the importance of vaccination and vaccine efficiency rate during an ongoing pandemic.
methodsWe simulated a five compartment mathematical model to analyze the pandemic scenario in both California, and whole U.S. We considered four vaccines, Pfizer (95%), Moderna (94%), AstraZeneca (79%), and Johnson & Johnson (72%), which are being used rigorously to control the SARS-CoV-2 pandemic, in addition with two special cases: a vaccine with 100% efficacy rate and no vaccine under use. SARS-CoV-2 related data of California, and U.S. were used in this study.
findingsBoth the infection and death rates are very high in California. Our model suggests that the pandemic situation in California will be under control in the last quartile of the year 2023 if vaccination program is continued with the Pfizer vaccine. During this time, six waves may happen from the beginning of the immunization where the case fatality and recovery rates will be 1.697% and 98.30%, respectively. However, according to the considered model, this period might be extended to the mid of 2024 when vaccines with lower efficacy rates are used. On the other hand, the daily cases and deaths in the U.S. will be under control at the end of 2026 with multiple waves. Although the number of susceptible people will fall down to none in the beginning of 2027, there is less chance to stop the vaccination program if vaccinated with a vaccine other than a 100% effective vaccine or Pfizer, and at that case vaccination program must run till the mid of 2028. According to this study, the unconfirmed-infectious and infected cases will be under control at the end of 2027 and at the mid of 2028, respectively.
interpretationThe more effective a vaccine is, the less people suffer from this malign infection. Vaccines which are less than 90% effective do not have notable contribution to control the pandemic besides hard immunity. Furthermore, specific groups of people are getting prioritized initially, mass vaccination and quick responses are required to control the spread of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.